Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
| TPST Stock | USD 0.78 0.03 3.70% |
Slightly above 61% of Tempest Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that many traders are alarmed. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tempest |
BRISBANE, Calif., Aug. 23, 2024 -- Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing...
Read at globenewswire.com
 |
Tempest Therapeutics Fundamental Analysis
We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Tempest Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Tempest Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.
Peers
Tempest Therapeutics Related Equities
| AKTX | Akari Therapeutics | 8.05 | ||||
| LYEL | Lyell Immunopharma | 6.06 | ||||
| SANA | Sana Biotechnology | 5.35 | ||||
| INDP | Indaptus Therapeutics | 5.13 | ||||
| IKNA | Ikena Oncology | 4.65 | ||||
| ARMP | Armata Pharmaceuticals | 3.52 | ||||
| GLUE | Monte Rosa | 0.91 | ||||
| OLMA | Olema Pharmaceuticals | 0.24 | ||||
| RVMD | Revolution Medicines | 0.99 | ||||
| RNXT | RenovoRx | 1.05 | ||||
| ZNTL | Zentalis Pharmaceuticals | 2.60 | ||||
| RZLT | Rezolute | 2.90 | ||||
| ANEB | Anebulo Pharmaceuticals | 5.41 | ||||
| CGEM | Cullinan Oncology | 5.77 | ||||
| FBRX | Forte Biosciences | 6.12 | ||||
| PCSA | Processa Pharmaceuticals | 10.91 |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.